What You Should Know:
- Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation therapy: the Cala kIQ™ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease.
- The Cala kIQ System empowers patients and physicians by providing an on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when the patient undergoes intentional movement or posture.
Providing Clinically Meaningful Tremor Reduction
Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise. Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects.
The Cala kIQ System measures each patient’s unique tremor physiology and individualizes a stimulation pattern for tremor relief. The system is designed to be easy to use for patients and easy to manage for clinicians. Therapy is on-demand for patients and delivered via a wrist-worn wearable. Designed with patients in mind for comfort and usability, the system also offers online data insights through the MyCala.com patient portal. Patients and providers (should they choose to share it with them) can see therapy results over time and adjust treatment plans accordingly.
“At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor,” said Renee Ryan, CEO at Cala. “By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”
With a healthcare provider’s prescription, Veterans Affairs (VA) health systems will provide the Cala kIQ System at no cost to VA beneficiaries. Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson’s disease indication for the Cala kIQ System and will share updates as available.
